Sarepta Therapeutics Inc. had not revealed that it submitted a formal dispute resolution request appealing the US Food and Drug Administration's complete response letter for Vyondys 53 (golodirsen) so the announcement that the agency had approved the Duchenne muscular disease drug was surprising news.
Companies must file a Form 8-K with the Securities and Exchange Commission to announce certain types of material events
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?